You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
A federal judge last week ruled invalid the University of Rochester's sweeping claim to some lucrative anti-inflammatory drugs, dismissing the patent as "little more than a research plan." The university will appeal the ruling, which legal experts say could rein in inventors making similarly broad claims based on basic research findings.
